Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352155 | 0.88 | MAOB (0.39) | MAOBL3MBTL1ATMALDH1A1MAPT | |
| SCHEMBL16352111 | 0.88 | L3MBTL1 (0.45) | MAOBL3MBTL1ALDH1A1 | |
| SCHEMBL16352148 | 0.87 | LTB4R (0.38) | MAOBL3MBTL1ALDH1A1 | |
| SCHEMBL16352143 | 0.86 | RXRA (0.39) | NPC1RAB9AL3MBTL1ATMALDH1A1 | |
| SCHEMBL16352150 | 0.83 | ATM (0.44) | MAOBNPC1RAB9AATMMAPK1 | |
| SCHEMBL16352151 | 0.83 | EPHX1 (0.40) | L3MBTL1 | |
| SCHEMBL16352144 | 0.81 | SIGMAR1 (0.38) | MAOBRAB9ACYP1A2ATM | |
| SCHEMBL16352146 | 0.79 | MET (0.37) | MAOBNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL16352152 | 0.79 | MTNR1B (0.34) | L3MBTL1 | |
| SCHEMBL16352153 | 0.79 | MAOB (0.43) | MAOBPARP10AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593136-B2 | Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase | THE GEORGE WASHINGTON UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | DCXR, G6PD, GRHPR | MAOB 1531/4885NPC1 4548/4885RAB9A 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.